TrialBlood advances2023

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.

Stephen M Ansell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.